Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i>

Antimicrobial resistance spurred by the overuse and misuse of antibiotics is a major global health concern, and of the Gram positive bacteria, <i>S. aureus</i> is a leading cause of mortality and morbidity. Alternative strategies to treat <i>S. aureus</i> infections, such as...

Full description

Bibliographic Details
Main Authors: Beata Chudzik-Rząd, Anna Malm, Nazar Trotsko, Monika Wujec, Tomasz Plech, Agata Paneth
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/25/10/2302
id doaj-01f1302fc6f5433c93db637ec3ab3193
record_format Article
spelling doaj-01f1302fc6f5433c93db637ec3ab31932020-11-25T03:12:47ZengMDPI AGMolecules1420-30492020-05-01252302230210.3390/molecules25102302Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i>Beata Chudzik-Rząd0Anna Malm1Nazar Trotsko2Monika Wujec3Tomasz Plech4Agata Paneth5Department of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Faculty of Pharmacy, Medical University of Lublin, Chodźki 1, 20-093 Lublin, PolandDepartment of Pharmaceutical Microbiology with Laboratory for Microbiological Diagnostics, Faculty of Pharmacy, Medical University of Lublin, Chodźki 1, 20-093 Lublin, PolandDepartment of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4a, 20-093 Lublin, PolandDepartment of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4a, 20-093 Lublin, PolandDepartment of Pharmacology, Faculty of Health Sciences, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, PolandDepartment of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4a, 20-093 Lublin, PolandAntimicrobial resistance spurred by the overuse and misuse of antibiotics is a major global health concern, and of the Gram positive bacteria, <i>S. aureus</i> is a leading cause of mortality and morbidity. Alternative strategies to treat <i>S. aureus</i> infections, such as combination therapy, are urgently needed. In this study, a checkerboard method was used to evaluate synergistic interactions between nine thiosemicarbazides (4-benzoyl-1-(2,3-dichloro-benzoyl)thiosemicarbazides <b>1</b>–<b>5</b> and 4-aryl-1-(2-fluorobenzoyl)thiosemicarbazides <b>6</b>–<b>9</b>) and conventional antibiotics against <i>S. aureus</i> ATCC 25923, which were determined as the fractional inhibitory concentration indices (FICIs). For these experiments, amoxicillin, gentamicin, levofloxacin, linezolid, and vancomycin were selected to represent the five antimicrobial classes most commonly used in clinical practice. With one exception of <b>7</b>-vancomycin combination, none of the forty-five thiosemicarbazide-antibiotic combinations tested had an antagonistic effect, showing promising results with respect to a combination therapy. The synergic effect was observed for the <b>2</b>-linezolid, <b>4</b>-levofloxacin, <b>5</b>-linezolid, <b>6</b>-gentamicin, <b>6</b>-linezolid, and <b>7</b>-levofloxacin combinations. No interactions were seen in combination of the thiosemicarbazide with gentamicin or vancomycin, whereas all combinations with linezolid acted in additive or synergism, except for <b>6</b>-gentamicin and <b>7</b>-linezolid. The 4-(4-chlorophenyl)-1-(2-fluorobenzoyl)thiosemicarbazide <b>6</b> showed a clear preference for the potency; it affected synergistically in combinations with gentamicin or linezolid and additively in combinations with amoxicillin, levofloxacin, or vancomycin. In further studies, the inhibitory potency of the thiosemicarbazides against <i>S. aureus</i> DNA gyrase and topoisomerase IV was examined to clarify the molecular mechanism involved in their synergistic effect in combination with levofloxacin. The most potent synergist <b>6</b> at concentration of 100 µM was able to inhibit ~50% activity of <i>S. aureus</i> DNA gyrase, thereby suggesting that its anti-gyrase activity, although weak, may be a possible factor contributing to its synergism effect in combination with linezolid or gentamycin.https://www.mdpi.com/1420-3049/25/10/2302thiosemicarbazidesantibacterial activitysynergistic effectbacterial topoisomerases
collection DOAJ
language English
format Article
sources DOAJ
author Beata Chudzik-Rząd
Anna Malm
Nazar Trotsko
Monika Wujec
Tomasz Plech
Agata Paneth
spellingShingle Beata Chudzik-Rząd
Anna Malm
Nazar Trotsko
Monika Wujec
Tomasz Plech
Agata Paneth
Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i>
Molecules
thiosemicarbazides
antibacterial activity
synergistic effect
bacterial topoisomerases
author_facet Beata Chudzik-Rząd
Anna Malm
Nazar Trotsko
Monika Wujec
Tomasz Plech
Agata Paneth
author_sort Beata Chudzik-Rząd
title Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i>
title_short Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i>
title_full Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i>
title_fullStr Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i>
title_full_unstemmed Synergistic Effects of Thiosemicarbazides with Clinical Drugs against <i>S. aureus</i>
title_sort synergistic effects of thiosemicarbazides with clinical drugs against <i>s. aureus</i>
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2020-05-01
description Antimicrobial resistance spurred by the overuse and misuse of antibiotics is a major global health concern, and of the Gram positive bacteria, <i>S. aureus</i> is a leading cause of mortality and morbidity. Alternative strategies to treat <i>S. aureus</i> infections, such as combination therapy, are urgently needed. In this study, a checkerboard method was used to evaluate synergistic interactions between nine thiosemicarbazides (4-benzoyl-1-(2,3-dichloro-benzoyl)thiosemicarbazides <b>1</b>–<b>5</b> and 4-aryl-1-(2-fluorobenzoyl)thiosemicarbazides <b>6</b>–<b>9</b>) and conventional antibiotics against <i>S. aureus</i> ATCC 25923, which were determined as the fractional inhibitory concentration indices (FICIs). For these experiments, amoxicillin, gentamicin, levofloxacin, linezolid, and vancomycin were selected to represent the five antimicrobial classes most commonly used in clinical practice. With one exception of <b>7</b>-vancomycin combination, none of the forty-five thiosemicarbazide-antibiotic combinations tested had an antagonistic effect, showing promising results with respect to a combination therapy. The synergic effect was observed for the <b>2</b>-linezolid, <b>4</b>-levofloxacin, <b>5</b>-linezolid, <b>6</b>-gentamicin, <b>6</b>-linezolid, and <b>7</b>-levofloxacin combinations. No interactions were seen in combination of the thiosemicarbazide with gentamicin or vancomycin, whereas all combinations with linezolid acted in additive or synergism, except for <b>6</b>-gentamicin and <b>7</b>-linezolid. The 4-(4-chlorophenyl)-1-(2-fluorobenzoyl)thiosemicarbazide <b>6</b> showed a clear preference for the potency; it affected synergistically in combinations with gentamicin or linezolid and additively in combinations with amoxicillin, levofloxacin, or vancomycin. In further studies, the inhibitory potency of the thiosemicarbazides against <i>S. aureus</i> DNA gyrase and topoisomerase IV was examined to clarify the molecular mechanism involved in their synergistic effect in combination with levofloxacin. The most potent synergist <b>6</b> at concentration of 100 µM was able to inhibit ~50% activity of <i>S. aureus</i> DNA gyrase, thereby suggesting that its anti-gyrase activity, although weak, may be a possible factor contributing to its synergism effect in combination with linezolid or gentamycin.
topic thiosemicarbazides
antibacterial activity
synergistic effect
bacterial topoisomerases
url https://www.mdpi.com/1420-3049/25/10/2302
work_keys_str_mv AT beatachudzikrzad synergisticeffectsofthiosemicarbazideswithclinicaldrugsagainstisaureusi
AT annamalm synergisticeffectsofthiosemicarbazideswithclinicaldrugsagainstisaureusi
AT nazartrotsko synergisticeffectsofthiosemicarbazideswithclinicaldrugsagainstisaureusi
AT monikawujec synergisticeffectsofthiosemicarbazideswithclinicaldrugsagainstisaureusi
AT tomaszplech synergisticeffectsofthiosemicarbazideswithclinicaldrugsagainstisaureusi
AT agatapaneth synergisticeffectsofthiosemicarbazideswithclinicaldrugsagainstisaureusi
_version_ 1724648562067767296